Chimeric antigen receptor engineered T cells (CAR-T cells) have made remarkable strides in the treatment of patients with B cell malignancies exemplified by anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL.). This success however has encountered hurdles in translation across hematological malignancies and even more so in solid tumors.
We welcome proposals aimed at the development of novel CAR-engineered T cell products against solid and/or hematological malignancies. Proposals aimed at overcoming limitations such as tumor selective expression, heterogeneous antigen expression, immunosuppressive networks in the tumor microenvironment, optimal CAR construct, T cell function and persistence, and inadequate trafficking are desired.
Along with the recent remarkable changes in modality for cancer therapy, like immuno-checkpoint inhibitors and CAR-T cells, other cancer immuno-therapy which is completely different from the traditional cancer therapies has been actively developed. In this subject, we are looking for innovative ideas and related technologies for cancer immuno-therapy applicable to cell therapy. As CAR-T cells are covered in subject 13, so we are seeking new proposals that are not related to CAR-T cells and will lead to differentiation from existing cancer therapies.
Follow the procedure below to make an application.
After submission, your website will show the “Submission Completed” page and you will receive a confirmation email.
Please contact the COCKPI-T® Funding Office for further information.
* Please be aware that we may not be able to respond to every inquiry.